Stock Market News8 hours SNY’s Sarclisa Gets EU Nod for Expanded Use in Multiple Myeloma Zacks
The latest decision makes Sanofi’s Sarclisa the first anti-CD38 therapy for transplant-ineligible patients with front-line multiple myeloma in the EU.
XThe latest decision makes Sanofi’s Sarclisa the first anti-CD38 therapy for transplant-ineligible patients with front-line multiple myeloma in the EU.
X